Gossamer Bio (GOSS) Stock Analysis

What Gossamer Bio does

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Key metrics

ETFs linked to GOSS

Broad-market and Healthcare sector ETFs an investor holding Gossamer Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GOSS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Gossamer Bio?

Gossamer Bio trades under the ticker GOSS on NASDAQ.

Which exchange is GOSS listed on?

GOSS is listed on NASDAQ.

What sector does Gossamer Bio operate in?

Gossamer Bio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GOSS in a portfolio?

PortView shows GOSS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.